文献速递腹部CTMRUS

胰腺局灶性病变多学科团队管理的系统综述

Effectiveness of multidisciplinary team collaboration in focal pancreatic lesion management: a systematic review.
PubMed 文献 · Abdom Radiol (NY) · 2026-06-08

本系统综述遵循PRISMA指南并注册于PROSPERO,检索PubMed、Scopus和CENTRAL至2025年4月14日,纳入20项研究、14366例患者。结果显示MDT审查使17.6%–37.9%的病例主要诊断发生改变,18.7%–31.5%的病例分期或可切除性评估改变,18%–72%的初始治疗方案被修改。MDT管理显著提高R0切除率(OR 5.47),但对总生存期的影响在各文献中不一致。

要点

  • MDT复查影像与病理后,近两成至三成胰腺局灶病变的主要诊断或分期可切除性评估发生改变。
  • MDT修改初始治疗方案的比例为18%–72%,可减少非治疗性剖腹探查术。
  • MDT管理显著提高R0切除可能性(OR 5.47),但生存获益尚不一致。

核心结论

  • MDT主导的诊疗从根本上改善胰腺局灶性病变的管理,提升诊断准确性、优化治疗计划并提高指南依从性。
  • MDT管理显著提高R0切除率(OR 5.47),但对总生存期的影响在纳入文献中不一致。
  • 现有证据虽多为回顾性,仍强烈支持将MDT作为胰腺局灶性病变不可或缺的标准诊疗模式。

研究设计与样本

  • 系统综述,遵循PRISMA指南并注册于PROSPERO(CRD420251142032)。
  • 检索PubMed、Scopus和CENTRAL数据库,截止2025年4月14日,纳入20项研究,共14366例患者。
  • 由三名独立评审者完成筛选与数据提取,分歧由第四名评审者裁决。

关键影像表现/征象

  • MDT对影像和病理进行专家再评估后,17.6%–37.9%的病例主要诊断发生改变。
  • 18.7%–31.5%的患者在MDT复查后临床分期或可切除性评估发生改变。
  • MDT后初始管理方案修改比例为18%–72%,非治疗性剖腹探查术显著减少。

诊断标准与关键数值

  • 主要诊断改变率:17.6%–37.9%。
  • 临床分期或可切除性评估改变率:18.7%–31.5%。
  • 初始管理方案修改率:18%–72%。
  • MDT管理与R0切除的OR为5.47。

临床应用与阅片要点

  • 放射科和超声科医生应参与胰腺局灶性病变MDT,对影像进行结构化再评估以降低分期与可切除性误判。
  • MDT修正影像解读可改变近三成病例的诊断与可切除性判断,直接影响治疗路径选择。
  • 关注MDT后治疗方案变化,尤其新辅助治疗、姑息转诊和临床试验入组的增加。

局限性

  • 纳入证据以回顾性研究为主。
  • MDT对总生存期的影响在文献中不一致,缺乏统一结论。
  • 原文未报告纳入研究的设备、序列及影像征象细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The diagnosis and management of focal pancreatic lesions is complex with diagnostic uncertainty and inconsistent guidelines. While multidisciplinary teams (MDTs) have emerged as the standard of care to navigate this challenge, a comprehensive synthesis of their impact is absent from literature. This systematic review aims to consolidate evidence on how formal MDT-led care influences diagnostic accuracy, treatment decisions and timelines, guideline compliance, and clinical outcomes for this diverse patient population.

METHODS: This systematic review was conducted following the PRISMA guidelines and was registered on PROSPERO. We searched PubMed, Scopus, and CENTRAL through 14 April 2025 to identify studies evaluating the impact of MDTs on the management of focal pancreatic lesions. Three independent reviewers performed screening and data extraction, with conflicts resolved by a fourth reviewer.

RESULTS: Our systematic review included 20 studies encompassing 14,366 patients. MDT review led to a change in primary diagnosis in 17.6% to 37.9% of cases and altered clinical stage or resectability assessment in 18.7% to 31.5% of patients following expert re-evaluation of imaging and pathology. Consequently, the initial management plan was modified in 18% to 72% of cases. This consistently improved patient selection, with increased use of neoadjuvant therapy, higher rates of guideline-concordant care and clinical trial enrollment, and more frequent referral to palliative care, significantly reducing non-therapeutic laparotomies. While MDT management was associated with a significantly higher likelihood of achieving a complete (R0) surgical resection (OR 5.47), its impact on overall survival was inconsistent across the reviewed literature.

CONCLUSION: This systematic review provides substantial evidence that MDT-led care fundamentally improves the management of focal pancreatic lesions. MDT implementation consistently enhanced diagnostic accuracy, optimized treatment planning, and increased guideline-concordant care, leading to improved surgical outcomes. While the evidence is largely retrospective, these benefits strongly support the MDT as an indispensable standard of care. Future research should focus on optimizing the MDT model's structure, quality, and cost-effectiveness to maximize patient benefit globally.

TRIAL REGISTRATION: PROSPERO (CRD420251142032).

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Abdullah, Zaheer, Lodhi, et al. Effectiveness of multidisciplinary team collaboration in focal pancreatic lesion management: a systematic review. Abdom Radiol (NY). 2026. PMID: 42257900. doi:10.1007/s00261-026-05554-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。